Monitoring influenza virus susceptibility to oseltamivir using a new rapid assay, iART

Gubareva, Larisa V.; Fallows, Eric; Mishin, Vasiliy P.; Hodges, Erin; Brooks, Abdullah; Barnes, John; Fry, Alicia M.; Kramp, William; Shively, Roxanne; Wentworth, David E.; Weidemaier, Kristin; Jacobson, Ross

doi:10.2807/1560-7917.es.2017.22.18.30529

Cited by 7 publications

(10 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Simple and rapid assays that can be used by surveillance laboratories and in clinical settings are needed to detect viruses with reduced susceptibility to NAIs. As previously reported, the prototype influenza antiviral resistance test (iART), developed by BD Technologies (BARDA Contract HHSO100201300008C), is able to phenotypically detect seasonal influenza viruses that display RI/HRI by oseltamivir . This assay compares influenza‐specific sialidase (NA) activity with and without a single drug concentration, requires only 1 hour, and does not need extensive training to carry out.…”

Section: Introductionmentioning

confidence: 60%

“…Alternatively, any specimen with an R ‐factor above 0.50 could be flagged for sequence analysis and additional testing in the NAI assay. None of the wild‐type type viruses shown in Table or seasonal viruses reported previously would be flagged as having potentially reduced susceptibility using a lower threshold for type A viruses …”

Section: Comparison Of Iart To Nai Assaymentioning

confidence: 99%

“…Notably, iART was able to detect resistance caused by R292K, without modifying the pH conditions of the assay. We previously showed that clinical specimens can be tested directly by iART, even when NA activity is insufficient for testing by NAI . These results confirm and extend those findings and suggest the greater sensitivity of iART to detect resistance in low‐activity NA viruses.…”

Section: Iart Vs Nai Assay Under Low Ph Conditions (Ph 53 Vs 68)mentioning

confidence: 99%

“…As previously reported, the prototype influenza antiviral resistance test (iART), developed by BD Technologies (BARDA Contract HHSO100201300008C), is able to phenotypically detect seasonal influenza viruses that display RI/HRI by oseltamivir. 7 This assay compares influenza-specific sialidase (NA) activity with and without a single drug concentration, requires only 1 hour, and does not need extensive training to carry out. Here, we present similar findings for zoonotic and animal influenza viruses.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Detection of oseltamivir‐resistant zoonotic and animal influenza A viruses using the rapid influenza antiviral resistance test

Hodges

et al. 2019

Influenza Resp Viruses

Self Cite

View full text Add to dashboard Cite

Mutations in the influenza virus neuraminidase (NA) that cause reduced susceptibility to the NA inhibitor (NAI) oseltamivir may occur naturally or following antiviral treatment. Currently, detection uses either a traditional NA inhibition assay or gene sequencing to identify known markers associated with reduced inhibition by oseltamivir. Both methods are laborious and require trained personnel. The influenza antiviral resistance test (iART), a prototype system developed by Becton, Dickinson and Company for research use only, offers a rapid and simple method to identify such viruses. This study investigated application of iART to influenza A viruses isolated from non‐human hosts with a variety of NA subtypes (N1‐N9).

show abstract

Section: Introductionmentioning

confidence: 60%

Section: Comparison Of Iart To Nai Assaymentioning

confidence: 99%

Section: Iart Vs Nai Assay Under Low Ph Conditions (Ph 53 Vs 68)mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Detection of oseltamivir‐resistant zoonotic and animal influenza A viruses using the rapid influenza antiviral resistance test

Hodges

et al. 2019

Influenza Resp Viruses

Self Cite

View full text Add to dashboard Cite

show abstract

“…In ferrets infected with WT virus, and treated with oseltamivir, resistant viruses with the R292K change emerged in 4/6 virus-infected ferrets on day 5 of treatment. The laboratory has tested the BD iART assay, designed for detection of resistant viruses in clinical samples (Gubareva et al, 2017). Pure populations with > 50-fold resistance were readily detected.…”

Section: Studies To Gain Insights Into Drug Resistance Of Influenza Amentioning

confidence: 99%

Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference

et al. 2018

View full text Add to dashboard Cite

The International Society for Influenza and other Respiratory Virus Diseases held its 5th Antiviral Group (isirv-AVG) Conference in Shanghai, China, in conjunction with the Shanghai Public Health Center and Fudan University from 14-16 June 2017. The three-day programme encompassed presentations on some of the clinical features, management, immune responses and virology of respiratory infections, including influenza A(H1N1)pdm09 and A(H7N9) viruses, MERS-CoV, SARS-CoV, adenovirus Type 80, enterovirus D68, metapneumovirus and respiratory syncytial virus (RSV). Updates were presented on several therapeutics currently in clinical trials, including influenza polymerase inhibitors pimodivir/JNJ6362387, S033188, favipiravir, monoclonal antibodies MHAA45449A and VIS410, and host directed strategies for influenza including nitazoxanide, and polymerase ALS-008112 and fusion inhibitors AK0529, GS-5806 for RSV. Updates were also given on the use of the currently licensed neuraminidase inhibitors. Given the location in China, there were also presentations on the use of Traditional Chinese Medicines. Following on from the previous conference, there were ongoing discussions on appropriate endpoints for severe influenza in clinical trials from regulators and clinicians, an issue which remains unresolved. The aim of this conference summary is to provide information for not only conference participants, but a detailed referenced review of the current status of clinical trials, and pre-clinical development of therapeutics and vaccines for influenza and other respiratory diseases for a broader audience.

show abstract

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016–2017

et al. 2018

View full text Add to dashboard Cite

A total of 13672 viruses, collected by World Health Organization recognised National Influenza Centres between May 2016 and May 2017, were assessed for neuraminidase inhibitor susceptibility by four WHO Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance Epidemiology and Control of Influenza. The 50% inhibitory concentration (IC50) was determined for oseltamivir and zanamivir for all viruses, and for peramivir and laninamivir in a subset (n = 8457). Of the viruses tested, 94% were obtained from the Western Pacific, Americas and European WHO regions, while limited viruses were available from the Eastern Mediterranean, African and South East Asian regions.Reduced inhibition (RI) by one or more neuraminidase inhibitor was exhibited by 0.2% of viruses tested (n = 32). The frequency of viruses with RI has remained low since this global analysis began (2015/16: 0.8%, 2014/15: 0.5%; 2013/14: 1.9%; 2012/13: 0.6%) but 2016/17 has the lowest frequency observed to date. Analysis of 13581 neuraminidase sequences retrieved from public databases, of which 5243 sequences were from viruses not included in the phenotypic analyses, identified 58 further viruses (29 without phenotypic analyses) with amino acid substitutions associated with RI by at least one neuraminidase inhibitor. Bringing the total proportion to 0.5% (90/18915).This 2016/17 analysis demonstrates that neuraminidase inhibitors remain suitable for treatment and prophylaxis of influenza virus infections, but continued monitoring is important. An expansion of surveillance testing is paramount since several novel influenza antivirals are in late stage clinical trials with some resistance already having been identified.

show abstract

Monitoring influenza virus susceptibility to oseltamivir using a new rapid assay, iART

Cited by 7 publications

References 16 publications

Detection of oseltamivir‐resistant zoonotic and animal influenza A viruses using the rapid influenza antiviral resistance test

Detection of oseltamivir‐resistant zoonotic and animal influenza A viruses using the rapid influenza antiviral resistance test

Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016–2017

Contact Info

Product

Resources

About